# US 2026/0284136 A1 · Compositions containing kratom compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0284136 A1
- Document ID: US20260284136A1
- Status: Published application
- Kind: A1
- Application number: 19/690,815
- Filed: 2026-05-28
- Published: 2026-09-24
- Earliest claimed: 2019-10-16
- Assignees: Caamtech, Inc.
- Applicants: Caamtech, Inc.
- Inventors: Andrew R. CHADEAYNE
- Web page: https://patentgrep.com/patent/US20260284136A1

## CPC

- A61K 36/74: Rubiaceae (Madder family)
- A61K 31/4375: the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Disclosed are compositions containing (a) a purified kratom compound chosen from the following: 7-Hydroxymitragynine, Mitragynine, Paynantheine, Speciociliatine, Speciogynine, Ajmalicine, Ciliaphylline, Corynantheidine, Corynoxine A, Corynoxine B, Isomitraphylline, Isorhynchophylline, Mitraphylline, Rhynchophylline, Speciophylline, Speciofoline, Epicatechin, 7-Hydroxyspecioliatine, 9-Hydroxycorynantheidine, Corynoxeine, Isopteropodine, Isorhynchophylline Oxindole, Tetrahydroalstonine, Mitragynine Oxindole B, and Mitragynine Oxindole A or the salts of these kratom compounds; and (b) a second active compound selected from a serotonergic drug, a purified psilocybin derivative, a purified cannabinoid, or a purified terpene. The disclosure also relates to formulations, including pharmaceutical formulations, of such a composition and an excipient. Also disclosed are methods of regulating the activity of a neurotransmitter receptor and methods of treating a psychological disorder, a compulsive disorder, or a depressive disorder.

## Claims

### Claim 1

An engineered and unnatural formulation comprising:
a first purified kratom compound and a second purified kratom compound,
wherein the first purified kratom compound is different from the second purified kratom compound, and
wherein the formulation is substantially free from a third kratom compound.

### Claim 2 (depends on 1)

The formulation of claim 1, wherein the first purified kratom compound is 7-hydroxymitragynine and the second purified kratom compound is selected from the group consisting of speciociliatine, speciogynine, paynantheine, corynantheidine, isomitraphylline, mitraphylline, corynoxeine, isorhynchophylline, and rhynchophylline, wherein the third kratom compound that the formulation is substantially free from is mitragynine.

### Claim 3 (depends on 1)

The formulation of claim 1, further comprising a purified terpene.

### Claim 4 (depends on 3)

The formulation of claim 3, wherein the purified terpene is selected from the group consisting of limonene, linalool, eugenol, geraniol, citronellol, pinene, beta-myrcene, carvone, anethole, and menthol.

### Claim 5 (depends on 2)

The formulation of claim 2, further comprising a purified terpene.

### Claim 6 (depends on 5)

The formulation of claim 5, wherein the purified terpene is selected from the group consisting of limonene, linalool, eugenol, geraniol, citronellol, pinene, beta-myrcene, carvone, anethole, and menthol.
